|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:ARL15-CDC42SE2 (FusionGDB2 ID:6560) |
Fusion Gene Summary for ARL15-CDC42SE2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ARL15-CDC42SE2 | Fusion gene ID: 6560 | Hgene | Tgene | Gene symbol | ARL15 | CDC42SE2 | Gene ID | 54622 | 56990 |
| Gene name | ADP ribosylation factor like GTPase 15 | CDC42 small effector 2 | |
| Synonyms | ARFRP2 | SPEC2 | |
| Cytomap | 5q11.2 | 5q31.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | ADP-ribosylation factor-like protein 15ADP-ribosylation factor-like 15ADP-ribosylation factor-related protein 2ARF-related protein 2 | CDC42 small effector protein 2non-kinase Cdc42 effector protein SPEC2small effector of CDC42 protein 2 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q9NXU5 | Q9NRR3 | |
| Ensembl transtripts involved in fusion gene | ENST00000504924, ENST00000507646, ENST00000502271, ENST00000510591, | ENST00000360515, ENST00000503291, ENST00000505065, ENST00000504701, ENST00000395246, | |
| Fusion gene scores | * DoF score | 18 X 13 X 7=1638 | 8 X 9 X 3=216 |
| # samples | 18 | 10 | |
| ** MAII score | log2(18/1638*10)=-3.18586654531133 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(10/216*10)=-1.11103131238874 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ARL15 [Title/Abstract] AND CDC42SE2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | ARL15(53409032)-CDC42SE2(130721236), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | CDC42SE2 | GO:0009966 | regulation of signal transduction | 10816584 |
| Fusion gene breakpoints across ARL15 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across CDC42SE2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | BRCA | TCGA-C8-A134-01A | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
Top |
Fusion Gene ORF analysis for ARL15-CDC42SE2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-5UTR | ENST00000504924 | ENST00000360515 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5CDS-5UTR | ENST00000504924 | ENST00000503291 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5CDS-5UTR | ENST00000504924 | ENST00000505065 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5CDS-5UTR | ENST00000507646 | ENST00000360515 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5CDS-5UTR | ENST00000507646 | ENST00000503291 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5CDS-5UTR | ENST00000507646 | ENST00000505065 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5CDS-intron | ENST00000504924 | ENST00000504701 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5CDS-intron | ENST00000507646 | ENST00000504701 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-3CDS | ENST00000502271 | ENST00000395246 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-3CDS | ENST00000510591 | ENST00000395246 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-5UTR | ENST00000502271 | ENST00000360515 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-5UTR | ENST00000502271 | ENST00000503291 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-5UTR | ENST00000502271 | ENST00000505065 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-5UTR | ENST00000510591 | ENST00000360515 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-5UTR | ENST00000510591 | ENST00000503291 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-5UTR | ENST00000510591 | ENST00000505065 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-intron | ENST00000502271 | ENST00000504701 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| 5UTR-intron | ENST00000510591 | ENST00000504701 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| In-frame | ENST00000504924 | ENST00000395246 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| In-frame | ENST00000507646 | ENST00000395246 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000504924 | ARL15 | chr5 | 53409032 | - | ENST00000395246 | CDC42SE2 | chr5 | 130721236 | + | 3544 | 556 | 1 | 756 | 251 |
| ENST00000507646 | ARL15 | chr5 | 53409032 | - | ENST00000395246 | CDC42SE2 | chr5 | 130721236 | + | 3547 | 559 | 1 | 759 | 252 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000504924 | ENST00000395246 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + | 0.000482285 | 0.9995177 |
| ENST00000507646 | ENST00000395246 | ARL15 | chr5 | 53409032 | - | CDC42SE2 | chr5 | 130721236 | + | 0.00048294 | 0.9995171 |
Top |
Fusion Genomic Features for ARL15-CDC42SE2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| ARL15 | chr5 | 53409031 | - | CDC42SE2 | chr5 | 130721235 | + | 5.22E-06 | 0.99999475 |
| ARL15 | chr5 | 53409031 | - | CDC42SE2 | chr5 | 130721235 | + | 5.22E-06 | 0.99999475 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for ARL15-CDC42SE2 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:53409032/chr5:130721236) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ARL15 | CDC42SE2 |
| FUNCTION: Probably involved in the organization of the actin cytoskeleton by acting downstream of CDC42, inducing actin filament assembly. Alters CDC42-induced cell shape changes. In activated T-cells, may play a role in CDC42-mediated F-actin accumulation at the immunological synapse. May play a role in early contractile events in phagocytosis in macrophages. {ECO:0000269|PubMed:10816584, ECO:0000269|PubMed:15840583}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | ARL15 | chr5:53409032 | chr5:130721236 | ENST00000504924 | - | 4 | 5 | 142_145 | 154 | 205.0 | Nucleotide binding | GTP |
| Hgene | ARL15 | chr5:53409032 | chr5:130721236 | ENST00000504924 | - | 4 | 5 | 39_46 | 154 | 205.0 | Nucleotide binding | GTP |
| Hgene | ARL15 | chr5:53409032 | chr5:130721236 | ENST00000504924 | - | 4 | 5 | 82_86 | 154 | 205.0 | Nucleotide binding | GTP |
| Tgene | CDC42SE2 | chr5:53409032 | chr5:130721236 | ENST00000360515 | 2 | 6 | 20_23 | 18 | 978.6666666666666 | Compositional bias | Note=Poly-Arg | |
| Tgene | CDC42SE2 | chr5:53409032 | chr5:130721236 | ENST00000395246 | 1 | 5 | 20_23 | 18 | 955.6666666666666 | Compositional bias | Note=Poly-Arg | |
| Tgene | CDC42SE2 | chr5:53409032 | chr5:130721236 | ENST00000505065 | 2 | 5 | 20_23 | 18 | 85.0 | Compositional bias | Note=Poly-Arg | |
| Tgene | CDC42SE2 | chr5:53409032 | chr5:130721236 | ENST00000360515 | 2 | 6 | 29_42 | 18 | 978.6666666666666 | Domain | CRIB | |
| Tgene | CDC42SE2 | chr5:53409032 | chr5:130721236 | ENST00000395246 | 1 | 5 | 29_42 | 18 | 955.6666666666666 | Domain | CRIB | |
| Tgene | CDC42SE2 | chr5:53409032 | chr5:130721236 | ENST00000505065 | 2 | 5 | 29_42 | 18 | 85.0 | Domain | CRIB |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for ARL15-CDC42SE2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >6560_6560_1_ARL15-CDC42SE2_ARL15_chr5_53409032_ENST00000504924_CDC42SE2_chr5_130721236_ENST00000395246_length(transcript)=3544nt_BP=556nt GTTGCTGGCTTTTTCAGGAGCTGCTCGCTCGCAGCCAGAGACGCTGCTTTTTTTTTCCGGGTTCGGAGCCGTTCCGGATGCTTTAGGCTG CCGGATGTCTGATCTCCGAATAACTGAGGCGTTTCTGTACATGGATTATCTGTGTTTTAGAGCACTTTGCTGCAAGGGACCACCACCTGC ACGACCAGAATATGACCTGGTTTGCATAGGCCTCACAGGTTCTGGCAAAACCAGTCTGTTGTCCAAACTCTGCAGTGAAAGCCCCGATAA CGTCGTGTCGACCACAGGTTTTAGTATTAAAGCAGTGCCATTCCAGAATGCCATCTTGAATGTAAAAGAACTTGGAGGGGCTGATAACAT CCGGAAATACTGGAGCCGCTACTACCAAGGATCTCAAGGGGTAATATTTGTATTAGACAGTGCCTCTTCAGAGGATGATTTAGAAGCTGC TAGAAATGAGCTGCACTCAGCTCTTCAGCATCCACAGTTATGCACTTTACCCTTTTTAATATTGGCCAATCATCAAGACAAGCCAGCAGC TCGCTCAGTACAAGAGAAAAGGCGACGGCGGATTGACAGAAGTATGATTGGAGAGCCCACAAACTTTGTGCATACAGCTCATGTTGGATC AGGAGACCTGTTCAGTGGAATGAATTCAGTTAGCTCCATTCAGAACCAAATGCAGTCCAAGGGAGGTTATGGAGGTGGAATGCCTGCCAA TGTCCAGATGCAGCTCGTGGATACGAAGGCGGGATAGCCCTGGTCCTTTCTCCAAAGTGTGATGGCACCTTGTCCACCCTGTCGTGATTA TTCCAGTGAGATGTTACTGTTCTGCTCTGAAGAAGATACTGTCAGACGAATCCTGCATTTCCTTCAGCTGGCATGCATGCCTTTGGACTC ATGGACAGAGTTCTTTGGATTGTCACTGAATTTTCAATGTTTAATCAGTATGGATCTGATCTTCGCATGATCTTTTTTGTGAATGCTAAC ACCATTTTGCAGTTTTTTTTTTCTATTTTAAACATTTTTCTTTTCACTGCCGACCCCCTGCCTTACGATTTTATTGGAAAGCAAGGACCT GCTATTATTTGTTAATTTGCCATCATTTATGTATATTTTGGAAGGTATGAGACCCACAAGCACAATGATCATTTTTATTTGTTTGTTTGT TTGAAACTTCAGCAGAATAGATATCTGCATGCTTTATGAAGTTGTTGCTTCGGTAAGAGCCCATGGGATGCCAGAAATTAACATTTCTTT GCTGCCATGGGCTGATGATGCTGCTATTAGATAAAGTTTAGCTGTGGCACCAAGTCACATCATTTTCATAGAAAAAGATTACTTGTAGCT TATTTTAGAAGTATGACCTTTTGGTCTGTTTGATTGATTGATTAGAATTGCAATAAAAGAAAAGCTTGCATTCATAAGGCATTCATTCTG TTGTAAATGTTCAATATATTTATTTTGAGAGCAAGGACCTGTGGTTGTAAACAGGTGTGGTTACAGGTGTGGTTATGTATCTGAGTGTTG CGGTCATACTCTCCTCCAGTCCAATCCTGAGCATCTTCATCTTATTAATTAGCTGTTCGTTTCTTTGTGCACTCATTCTTTTATTTTTAC TTCTTTTTAATGTTATGGTATCCAGTTGTTTCCAGTAGCAGTTTCTTGAACTTCTGGCCTGTACTACTAACTGCAGACCTCCAGAGTCAC TGGCCTTTCTGTGCTCTACATATTATTTTAGGGGCCACATCAGTTGCCAAGAGCAACATACATACCGACCTGGCTGAATTATTGCCAGTG AAAACAACCTGTACGAAGCCTTTGCTCAGGTTCTAAAATATGTTTGTCCTTGCACGAATTTTGTATATTTCAAATATTTCTGTAAAGGTT TCTTCTTTTCTGTTAGAGTGTGGTGTTAAGCCAGAGTCAGTGGTTTGTGTTCTCATTAAAATGTTTGTTTAAATCCTATGTCCAATTCAA GCCTATCTAACTACATTTGGTAGGATTAACATTTCATATAACAAATGGGGCTTAATTAAAAACTTTAACTTGGAATAAAGGAACAGGGAT CACTTTATCTTCTGCCTTCATTTACCTTAGTCCAAGATTCTTGCAAAACAGGCAACTGAACAAACATTAGGTTTATGTAGGTAAAATGTG AAAGCATTTCTCCTCCACTTTTTAAAATTTAATTTACCCAGTACAGCGGGGCACCAGATTACTTGATCTTTGTATTTTGCAGTTTTGAGC CTTTGTGTCAATCCCAAGCACAGAGAGGATCTGCCAAGGAAAAACATTTGCATCTTCGGAGTAGACATTTTGCAGTTTGTTTAATAACAA CTTCTAAAGTAAGTTGAATTCATCCATTGTCACTGATTCACCAAGTGGATGTTGCATTGTGGAATTTGCCTGAGTACTGTTGTCATTCTG CTCAGCCAGGCACGGTCAGTTTCTTGGCCAGGGACATTGCTATGTGCTGTGTGCAAGCTCTTTAGAAGAGAGATTGGATTTTCTTGGCAT TATCAGCACTCATGCTATTTAGTCTACTTCTATTTTGACTGACTCTTTAAATTAGTACAATTTTTCTACTTGTCATATAACTCCTGGAAC AATAGTACGGGAAGCCGTGATCCTTTTCCCTGACTCATGATTTTAGTCTTTTTCCAAATCGCTGTTTTTTTTTTTTTTTTTTTTTTTTTT GCTGCTCCAACGACCAGCATGTGTTGGAGCAGATCTCCATGGTAAGCCAAAAGTGGACTTGTCAGCCTATAACTACTCTGCAGCTGCCAC TAACTCTACAGGCACAGTAACTACACTTTATACAGGAGCACATGCCAAAGTGCCTGGGAGGTGCCAATAAAATCAAGAAATAAGAAAACT ACAAAAAAAGATACGGTATTAACCTTGGACATAATTTTTTTTAGGGAGGCAGCTTTCCCACTTTTATAAAGGGGGTTGTAAATCTCAAGA GGTCATTTGTTCCCCATAGCAGCATATCTCATTTTTAAATTGAAGCGAATTAAATAGGATTTTACTACTCAACATTCATTATACTGTTAA TCTTTGCTGAAATATATGCTAACAAATGTTAAGCAAGGGAAACTGAAGACTTAGTCATGTGGATTGTTAGCAGTGATCTGCATTCTGTAA AAGAGGTACTTTCCCATGATGTAGGCATGAAGTGGTGCCAGTAAGCGTAGAGCGGAAATGTTGACTTTAGTTAACATTGGGTTTAGCATT TCCAGTGCAGCATTATCAGTGGGCCTTTAAAAATACTTCGTAAGTACATTAGCTTTCACTTTGTTGTTAAATTATAGCAGACTCATTATA GAGAACAAGTTTGCCTTGATTTTGTTTAAAATGACTTCTGCTAAGCACCCAGAAGATAAAATTGACATATTTTTATAATATAAGCATACT TTTTTTGTACATTGTGTTCATTCTTGAATAAAATGAGTTCTGTGTTGGCTTGTAGATACTAAAAAGAAAGTATTGATTTTGATTCAATAA >6560_6560_1_ARL15-CDC42SE2_ARL15_chr5_53409032_ENST00000504924_CDC42SE2_chr5_130721236_ENST00000395246_length(amino acids)=251AA_BP=185 LLAFSGAARSQPETLLFFSGFGAVPDALGCRMSDLRITEAFLYMDYLCFRALCCKGPPPARPEYDLVCIGLTGSGKTSLLSKLCSESPDN VVSTTGFSIKAVPFQNAILNVKELGGADNIRKYWSRYYQGSQGVIFVLDSASSEDDLEAARNELHSALQHPQLCTLPFLILANHQDKPAA -------------------------------------------------------------- >6560_6560_2_ARL15-CDC42SE2_ARL15_chr5_53409032_ENST00000507646_CDC42SE2_chr5_130721236_ENST00000395246_length(transcript)=3547nt_BP=559nt GCTGTTGCTGGCTTTTTCAGGAGCTGCTCGCTCGCAGCCAGAGACGCTGCTTTTTTTTTCCGGGTTCGGAGCCGTTCCGGATGCTTTAGG CTGCCGGATGTCTGATCTCCGAATAACTGAGGCGTTTCTGTACATGGATTATCTGTGTTTTAGAGCACTTTGCTGCAAGGGACCACCACC TGCACGACCAGAATATGACCTGGTTTGCATAGGCCTCACAGGTTCTGGCAAAACCAGTCTGTTGTCCAAACTCTGCAGTGAAAGCCCCGA TAACGTCGTGTCGACCACAGGTTTTAGTATTAAAGCAGTGCCATTCCAGAATGCCATCTTGAATGTAAAAGAACTTGGAGGGGCTGATAA CATCCGGAAATACTGGAGCCGCTACTACCAAGGATCTCAAGGGGTAATATTTGTATTAGACAGTGCCTCTTCAGAGGATGATTTAGAAGC TGCTAGAAATGAGCTGCACTCAGCTCTTCAGCATCCACAGTTATGCACTTTACCCTTTTTAATATTGGCCAATCATCAAGACAAGCCAGC AGCTCGCTCAGTACAAGAGAAAAGGCGACGGCGGATTGACAGAAGTATGATTGGAGAGCCCACAAACTTTGTGCATACAGCTCATGTTGG ATCAGGAGACCTGTTCAGTGGAATGAATTCAGTTAGCTCCATTCAGAACCAAATGCAGTCCAAGGGAGGTTATGGAGGTGGAATGCCTGC CAATGTCCAGATGCAGCTCGTGGATACGAAGGCGGGATAGCCCTGGTCCTTTCTCCAAAGTGTGATGGCACCTTGTCCACCCTGTCGTGA TTATTCCAGTGAGATGTTACTGTTCTGCTCTGAAGAAGATACTGTCAGACGAATCCTGCATTTCCTTCAGCTGGCATGCATGCCTTTGGA CTCATGGACAGAGTTCTTTGGATTGTCACTGAATTTTCAATGTTTAATCAGTATGGATCTGATCTTCGCATGATCTTTTTTGTGAATGCT AACACCATTTTGCAGTTTTTTTTTTCTATTTTAAACATTTTTCTTTTCACTGCCGACCCCCTGCCTTACGATTTTATTGGAAAGCAAGGA CCTGCTATTATTTGTTAATTTGCCATCATTTATGTATATTTTGGAAGGTATGAGACCCACAAGCACAATGATCATTTTTATTTGTTTGTT TGTTTGAAACTTCAGCAGAATAGATATCTGCATGCTTTATGAAGTTGTTGCTTCGGTAAGAGCCCATGGGATGCCAGAAATTAACATTTC TTTGCTGCCATGGGCTGATGATGCTGCTATTAGATAAAGTTTAGCTGTGGCACCAAGTCACATCATTTTCATAGAAAAAGATTACTTGTA GCTTATTTTAGAAGTATGACCTTTTGGTCTGTTTGATTGATTGATTAGAATTGCAATAAAAGAAAAGCTTGCATTCATAAGGCATTCATT CTGTTGTAAATGTTCAATATATTTATTTTGAGAGCAAGGACCTGTGGTTGTAAACAGGTGTGGTTACAGGTGTGGTTATGTATCTGAGTG TTGCGGTCATACTCTCCTCCAGTCCAATCCTGAGCATCTTCATCTTATTAATTAGCTGTTCGTTTCTTTGTGCACTCATTCTTTTATTTT TACTTCTTTTTAATGTTATGGTATCCAGTTGTTTCCAGTAGCAGTTTCTTGAACTTCTGGCCTGTACTACTAACTGCAGACCTCCAGAGT CACTGGCCTTTCTGTGCTCTACATATTATTTTAGGGGCCACATCAGTTGCCAAGAGCAACATACATACCGACCTGGCTGAATTATTGCCA GTGAAAACAACCTGTACGAAGCCTTTGCTCAGGTTCTAAAATATGTTTGTCCTTGCACGAATTTTGTATATTTCAAATATTTCTGTAAAG GTTTCTTCTTTTCTGTTAGAGTGTGGTGTTAAGCCAGAGTCAGTGGTTTGTGTTCTCATTAAAATGTTTGTTTAAATCCTATGTCCAATT CAAGCCTATCTAACTACATTTGGTAGGATTAACATTTCATATAACAAATGGGGCTTAATTAAAAACTTTAACTTGGAATAAAGGAACAGG GATCACTTTATCTTCTGCCTTCATTTACCTTAGTCCAAGATTCTTGCAAAACAGGCAACTGAACAAACATTAGGTTTATGTAGGTAAAAT GTGAAAGCATTTCTCCTCCACTTTTTAAAATTTAATTTACCCAGTACAGCGGGGCACCAGATTACTTGATCTTTGTATTTTGCAGTTTTG AGCCTTTGTGTCAATCCCAAGCACAGAGAGGATCTGCCAAGGAAAAACATTTGCATCTTCGGAGTAGACATTTTGCAGTTTGTTTAATAA CAACTTCTAAAGTAAGTTGAATTCATCCATTGTCACTGATTCACCAAGTGGATGTTGCATTGTGGAATTTGCCTGAGTACTGTTGTCATT CTGCTCAGCCAGGCACGGTCAGTTTCTTGGCCAGGGACATTGCTATGTGCTGTGTGCAAGCTCTTTAGAAGAGAGATTGGATTTTCTTGG CATTATCAGCACTCATGCTATTTAGTCTACTTCTATTTTGACTGACTCTTTAAATTAGTACAATTTTTCTACTTGTCATATAACTCCTGG AACAATAGTACGGGAAGCCGTGATCCTTTTCCCTGACTCATGATTTTAGTCTTTTTCCAAATCGCTGTTTTTTTTTTTTTTTTTTTTTTT TTTGCTGCTCCAACGACCAGCATGTGTTGGAGCAGATCTCCATGGTAAGCCAAAAGTGGACTTGTCAGCCTATAACTACTCTGCAGCTGC CACTAACTCTACAGGCACAGTAACTACACTTTATACAGGAGCACATGCCAAAGTGCCTGGGAGGTGCCAATAAAATCAAGAAATAAGAAA ACTACAAAAAAAGATACGGTATTAACCTTGGACATAATTTTTTTTAGGGAGGCAGCTTTCCCACTTTTATAAAGGGGGTTGTAAATCTCA AGAGGTCATTTGTTCCCCATAGCAGCATATCTCATTTTTAAATTGAAGCGAATTAAATAGGATTTTACTACTCAACATTCATTATACTGT TAATCTTTGCTGAAATATATGCTAACAAATGTTAAGCAAGGGAAACTGAAGACTTAGTCATGTGGATTGTTAGCAGTGATCTGCATTCTG TAAAAGAGGTACTTTCCCATGATGTAGGCATGAAGTGGTGCCAGTAAGCGTAGAGCGGAAATGTTGACTTTAGTTAACATTGGGTTTAGC ATTTCCAGTGCAGCATTATCAGTGGGCCTTTAAAAATACTTCGTAAGTACATTAGCTTTCACTTTGTTGTTAAATTATAGCAGACTCATT ATAGAGAACAAGTTTGCCTTGATTTTGTTTAAAATGACTTCTGCTAAGCACCCAGAAGATAAAATTGACATATTTTTATAATATAAGCAT ACTTTTTTTGTACATTGTGTTCATTCTTGAATAAAATGAGTTCTGTGTTGGCTTGTAGATACTAAAAAGAAAGTATTGATTTTGATTCAA >6560_6560_2_ARL15-CDC42SE2_ARL15_chr5_53409032_ENST00000507646_CDC42SE2_chr5_130721236_ENST00000395246_length(amino acids)=252AA_BP=186 LLLAFSGAARSQPETLLFFSGFGAVPDALGCRMSDLRITEAFLYMDYLCFRALCCKGPPPARPEYDLVCIGLTGSGKTSLLSKLCSESPD NVVSTTGFSIKAVPFQNAILNVKELGGADNIRKYWSRYYQGSQGVIFVLDSASSEDDLEAARNELHSALQHPQLCTLPFLILANHQDKPA -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for ARL15-CDC42SE2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ARL15-CDC42SE2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for ARL15-CDC42SE2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies